Neonatal Respiratory Distress Syndrome Treatment Market Report 2026

The neonatal respiratory distress syndrome treatment market size has grown strongly in recent years. It will grow from $1.03 billion in 2025 to $1.11 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to high premature birth rates, reliance on conventional oxygen therapy, limited access to neonatal intensive care units, early adoption of natural surfactants, increasing infant respiratory morbidity.

The neonatal respiratory distress syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $1.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to development of advanced synthetic surfactants, expansion of non-invasive ventilation technologies, rising investment in neonatal care equipment, increasing global awareness of neonatal complications, modernization of hospital respiratory support systems. Major trends in the forecast period include rising adoption of surfactant replacement therapies, increasing use of cpap and non-invasive ventilation, enhanced neonatal intensive care infrastructure, growing focus on premature birth management, rising development of synthetic and bioengineered surfactants.

The increasing incidence of premature births is expected to drive the growth of the neonatal respiratory distress syndrome (RDS) treatment market in the coming years. Premature births occur when an infant is delivered before 37 weeks of gestation, resulting in underdeveloped organ systems that require specialized medical care. One of the key factors contributing to rising premature birth rates is the growing prevalence of maternal health complications, which can disrupt normal fetal development and trigger early labor by placing physiological strain on both mother and fetus. Treatments for neonatal respiratory distress syndrome improve survival outcomes and stabilize premature infants, whose immature lungs make them highly vulnerable to respiratory failure. For example, in September 2024, Statistique Canada, a Canada-based governmental organization, reported that the proportion of births before 37 weeks increased slightly from 8.2% in 2022 to 8.3% in 2023, indicating a small upward trend in preterm births. Therefore, the rising rate of premature births is fueling demand for neonatal RDS treatments.

Leading companies in the neonatal respiratory distress syndrome treatment market are developing advanced solutions such as next-generation, portable nitric oxide delivery systems to enhance oxygenation, reduce treatment complications, and extend access beyond traditional NICU settings. Portable nitric oxide systems are medical devices that generate and deliver inhaled nitric oxide on demand, improving oxygenation and alleviating pulmonary hypertension in neonates with hypoxic respiratory failure, while enabling safe use during transport. For instance, in June 2025, Beyond Air Inc., a US-based medical device company, submitted a PMA supplement to the U.S. Food and Drug Administration for LungFit PH 2, a lighter, transport-ready nitric oxide generator using the company’s patented Ionizer technology. The device is designed for portability and convenience, providing continuous nitric oxide delivery while minimizing nitrogen dioxide production, ensuring safer therapy during neonatal transport. Additionally, phase-4 registry data for INOmax, an established iNO therapy by Mallinckrodt, continue to demonstrate real-world benefits in neonates with pulmonary hypertension, underscoring the clinical significance of inhaled nitric oxide in managing hypoxic respiratory failure.

In January 2024, Chiesi Group, an Italy-based biopharmaceutical company, partnered with Oak Hill Bio to develop neonatal therapies. The collaboration focuses on the development and commercialization of OHB-607, an innovative treatment aimed at preventing severe bronchopulmonary dysplasia (BPD) and its long-term respiratory consequences in preterm infants, particularly those born before 28 weeks of gestation with low IGF-1 levels. Oak Hill Bio, a UK-based company, specializes in therapies for neonatal and rare diseases.

Major companies operating in the neonatal respiratory distress syndrome treatment market are Medtronic Plc, GE Healthcare, Koninklijke Philips NV, Drägerwerk AG & Co. KGaA, Chiesi Farmaceutici, Fisher & Paykel Healthcare, Vyaire Medical, Laerdal Medical, Hamilton Medical, Inspiration Healthcare, Ventec Life Systems, Neotech Products, Windtree Therapeutics Inc., Discovery Laboratories Inc., ResMed Inc., Abbott Laboratories, Aerogen Pharma Corp., ONY Biotech, Yuhan Corporation, Atom Medical Corporation, Mindray Bio‑Medical Electronics, Getinge AB, Nihon Kohden Corporation, Siare Engineering Spa.

North America was the largest region in the neonatal respiratory distress syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neonatal respiratory distress syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neonatal respiratory distress syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs affect the neonatal respiratory distress syndrome treatment market by raising the cost of imported neonatal ventilators, CPAP systems, and surfactant therapy components used in NICUs. Regions reliant on neonatal care equipment imports, especially in Asia-Pacific and Europe, face price hikes and delays in equipment delivery. The most affected segments include oxygen therapy devices and surfactant supplies. Potential positive impacts include increased domestic production capacity and innovation in low-cost neonatal respiratory devices.

The neonatal respiratory distress syndrome treatment market research report is one of a series of new reports that provides neonatal respiratory distress syndrome treatment market statistics, including neonatal respiratory distress syndrome treatment industry global market size, regional shares, competitors with a neonatal respiratory distress syndrome treatment market share, detailed neonatal respiratory distress syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neonatal respiratory distress syndrome treatment industry. This neonatal respiratory distress syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neonatal respiratory distress syndrome treatment involves managing premature infants who have inadequate surfactant production, resulting in breathing difficulties. The treatment includes administering exogenous surfactant, providing respiratory support through mechanical ventilation or continuous positive airway pressure (CPAP), and supplementing oxygen as needed.

The main types of therapy for neonatal respiratory distress syndrome treatment are oxygen therapy and surfactant therapy. Oxygen therapy consists of delivering oxygen to patients who cannot obtain sufficient oxygen through normal breathing. It can be administered via inhalation, parenteral routes, and other methods, and is utilized by hospitals, sub-acute care facilities, home care providers, and retail pharmacies.

The neonatal respiratory distress syndrome treatment market consists of revenues earned by entities by providing services such as surfactant administration services, neonatal respiratory care consulting, telemedicine, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The neonatal respiratory distress syndrome treatment market also includes sales of mechanical ventilators, continuous positive airway pressure (CPAP) machines, high-frequency ventilators, and neonatal incubators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.